» Articles » PMID: 25892232

Central Role of ULK1 in Type I Interferon Signaling

Abstract

We provide evidence that the Unc-51-like kinase 1 (ULK1) is activated during engagement of the type I interferon (IFN) receptor (IFNR). Our studies demonstrate that the function of ULK1 is required for gene transcription mediated via IFN-stimulated response elements (ISRE) and IFNγ activation site (GAS) elements and controls expression of key IFN-stimulated genes (ISGs). We identify ULK1 as an upstream regulator of p38α mitogen-activated protein kinase (MAPK) and establish that the regulatory effects of ULK1 on ISG expression are mediated possibly by engagement of the p38 MAPK pathway. Importantly, we demonstrate that ULK1 is essential for antiproliferative responses and type I IFN-induced antineoplastic effects against malignant erythroid precursors from patients with myeloproliferative neoplasms. Together, these data reveal a role for ULK1 as a key mediator of type I IFNR-generated signals that control gene transcription and induction of antineoplastic responses.

Citing Articles

Interferon-driven Metabolic Reprogramming and Tumor Microenvironment Remodeling.

Chang T, Ho P Immune Netw. 2025; 25(1):e8.

PMID: 40078784 PMC: 11896656. DOI: 10.4110/in.2025.25.e8.


Physiological functions of ULK1/2.

Pareek G, Kundu M J Mol Biol. 2024; 436(15):168472.

PMID: 38311233 PMC: 11382334. DOI: 10.1016/j.jmb.2024.168472.


The nonautophagic functions of autophagy-related proteins.

Shang J, Yu C, Li R, Xi Y, Jian Y, Xu N Autophagy. 2023; 20(4):720-734.

PMID: 37682088 PMC: 11062363. DOI: 10.1080/15548627.2023.2254664.


Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells.

Saleiro D, Kosciuczuk E, Fischietti M, Perez R, Yang G, Eckerdt F Cancer Res Commun. 2023; 3(5):943-951.

PMID: 37377894 PMC: 10231401. DOI: 10.1158/2767-9764.CRC-23-0010.


Autophagy and Its Lineage-Specific Roles in the Hematopoietic System.

Hasan K, Haque M Oxid Med Cell Longev. 2023; 2023:8257217.

PMID: 37180758 PMC: 10171987. DOI: 10.1155/2023/8257217.


References
1.
Kiladjian J, Mesa R, Hoffman R . The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011; 117(18):4706-15. DOI: 10.1182/blood-2010-08-258772. View

2.
Kaur S, Sassano A, Joseph A, Majchrzak-Kita B, Eklund E, Verma A . Dual regulatory roles of phosphatidylinositol 3-kinase in IFN signaling. J Immunol. 2008; 181(10):7316-23. PMC: 2597572. DOI: 10.4049/jimmunol.181.10.7316. View

3.
Ivashkiv L, Donlin L . Regulation of type I interferon responses. Nat Rev Immunol. 2013; 14(1):36-49. PMC: 4084561. DOI: 10.1038/nri3581. View

4.
Kaur S, Kroczynska B, Sharma B, Sassano A, Arslan A, Majchrzak-Kita B . Critical roles for Rictor/Sin1 complexes in interferon-dependent gene transcription and generation of antiproliferative responses. J Biol Chem. 2014; 289(10):6581-6591. PMC: 3945321. DOI: 10.1074/jbc.M113.537852. View

5.
Bach M, Larance M, James D, Ramm G . The serine/threonine kinase ULK1 is a target of multiple phosphorylation events. Biochem J. 2011; 440(2):283-91. DOI: 10.1042/BJ20101894. View